Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
125,684,656
-
Total 13F shares
-
113,630,426
-
Share change
-
+7,330,240
-
Total reported value
-
$4,326,001,749
-
Put/Call ratio
-
37%
-
Price per share
-
$38.04
-
Number of holders
-
250
-
Value change
-
-$249,890,323
-
Number of buys
-
163
-
Number of sells
-
167
Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) as of Q3 2023
As of 30 Sep 2023,
Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) was held by
250 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
113,630,426 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, Avoro Capital Advisors LLC, EcoR1 Capital, LLC, VANGUARD GROUP INC, T. Rowe Price Investment Management, Inc., BlackRock Inc., JENNISON ASSOCIATES LLC, STATE STREET CORP, Octagon Capital Advisors LP, and FMR LLC.
This page lists
250
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.